Ad hoc announcement pursuant to art. 53 SIX Swiss Exchange Listing Rules
Sandoz launches biosimilar Pyzchiva® (ustekinumab) across Europe, to treat chronic inflammatory diseases
- Launch across Europe, starting today, strengthens well-established Sandoz immunology portfolio in Europe, leveraging existing footprint
- Pyzchiva® first ustekinumab biosimilar to launch in Europe with all reference medicine strengths, including 130mg vial initiation dose for Crohn's disease
- Pyzchiva® to treat adults with plaque psoriasis, psoriatic arthritis, Crohn's disease and pediatric plaque psoriasis
Basel, July 25, 2024 – Sandoz, the global leader in generic and biosimilar medicines, announces the launch of Pyzchiva®* (ustekinumab) across Europe, starting today. Pyzchiva®, developed and registered by Samsung Bioepis, is the first ustekinumab biosimilar to launch in Europe with all reference medicine strengths, including the 130mg vial initiation dose for Crohn's disease.
The launch strengthens our well-established immunology portfolio in Europe and leverages our existing footprint, with five biosimilars now marketed in this therapeutic area. Pyzchiva® is a key biosimilar driver, adding value and contributing to the company's mid-term growth strategy.
Rebecca Guntern, President Europe, Sandoz, said: “Timely and expanded access to safe, effective and affordable medicines can improve quality of life for millions of people living with chronic inflammatory diseases. Our goal is to make potentially life-changing medicines accessible to patients across Europe. Pyzchiva® is one of the first ustekinumab biosimilars in Europe, which marks a significant milestone on that road.”
Pyzchiva® is approved for treatment of adults with plaque psoriasis, psoriatic arthritis, Crohn's disease and pediatric plaque psoriasis for patients six years and older weighing over 60 kg.
Europe has the highest prevalence of psoriasis worldwide, affecting an estimated 6.4 million people and significantly impacting patients' quality of life.1,2 Plaque psoriasis is the most common form of psoriasis, affecting 85% to 90% of patients with psoriasis.3
Sandoz entered into a development and commercialization agreement for biosimilar ustekinumab with Samsung Bioepis in September 2023. Under the terms of the agreement, Sandoz has the right to commercialize Pyzchiva® in the US, Canada, the European Economic Area, Switzerland, and the UK. Samsung Bioepis remains responsible for development, registration, intellectual property, manufacturing, and supply.
*Pyzchiva® is a trademark of Samsung Bioepis Co. Ltd.
**Stelara® is a trademark of Johnson & Johnson
About Pyzchiva® (ustekinumab)
Pyzchiva® (ustekinumab) has been developed as a biosimilar with equivalent efficacy and comparable safety to the reference medicine Stelara®**, a human monoclonal antibody against interleukin (IL)-12/23. Pyzchiva® is approved for treatment of adults with plaque psoriasis, psoriatic arthritis, Crohn's disease and pediatric plaque psoriasis for patients six years and older weighing over 60 kg.
Pyzchiva® is available as a 130 mg concentrate in a vial for solution for infusion, additionally, a 90 mg and a 45 mg concentrate solution for injection in a pre-filled syringe.
Disclaimer
This Media Release contains forward-looking statements, which offer no guarantee with regard to future performance. These statements are made on the basis of management's views and assumptions regarding future events and business performance at the time the statements are made. They are subject to risks and uncertainties including, but not confined to, future global economic conditions, exchange rates, legal provisions, market conditions, activities by competitors and other factors outside of the control of Sandoz. Should one or more of these risks or uncertainties materialize or should underlying assumptions prove incorrect, actual outcomes may vary materially from those forecasted or expected. Each forward-looking statement speaks only as of the date of the particular statement, and Sandoz undertakes no obligation to publicly update or revise any forward-looking statements, except as required by law.
References
- International Federation of Psoriasis Associations (IFPA). Speaking up for psoriatic disease in Europe. Available at: https://cms.ifpa-pso.com/tools/20072022_IFPA-FORUM_Briefing-Book_Speaking-up.pdf [Last accessed July 2024].
- Frede N, et al. Psoriasis and Psoriatic Arthritis Have a Major Impact on Quality of Life and Depressive Symptoms: A Cross-Sectional Study of 300 Patients. Rheumatology and Therapy. 2023;10: 1655–1668. doi: 10.1007/s40744-023-00602-9.
- Palfreeman AC, McNamee KE, McCann FE. New developments in the management of psoriasis and psoriatic arthritis: a focus on apremilast. Drug Des Devel Ther. 2013;7:201-10.
About Sandoz
Sandoz (SIX: SDZ; OTCQX: SDZNY) is the global leader in generic and biosimilar medicines, with a growth strategy driven by its Purpose: pioneering access for patients. More than 20,000 people of more than 100 nationalities work together to ensure 800 million patient treatments are provided annually by Sandoz, generating substantial global healthcare savings and an even larger social impact. Its leading portfolio of approximately 1,500 products addresses diseases from the common cold to cancer. Headquartered in Basel, Switzerland, Sandoz traces its heritage back to 1886. Its history of breakthroughs includes Calcium Sandoz in 1929, the world's first oral penicillin in 1951, and the first biosimilar in 2006. In 2023, Sandoz recorded sales of USD 9.6 billion.
Global Media Relations contacts | Investor Relations contacts |
Global.MediaRelations@sandoz.com | Investor.Relations@sandoz.com |
Joerg E. Allgaeuer +49 171 838 4838 |
Karen M. King +1 609 722 0982 |
Chris Lewis +49 174 244 9501 |
Laurent de Weck +41 79 795 7364 |
-
Sandoz launches biosimilar Pyzchiva® (ustekinumab) across Europe, to treat chronic inflammatory diseAd hoc announcement pursuant to art. 53 SIX Swiss Exchange Listing Rules Sandoz launches biosimilar Pyzchiva® (ustekinumab) across Europe, to treat2024-07-25
-
中国西部天然展WPE&WHPE2024正式进入参展倒计时在健康意识日益增强的今天,功能性食品原料成为了连接自然与健康的重要桥梁。随着2024中国西部天然展WPE&WHPE的临近,一场关于健康、创新与合作的盛会即将在古都西2024-07-25
-
七一献礼丨热血铸就生命桥,爱心义诊温暖行为弘扬无偿献血的奉献精神,增强关爱他人的意识,7月19日上午,高新区市场监管局联合审协福建分中心、省知识产权保护中心举办“七一献礼·知产暖人心”团体无偿献血活2024-07-25
-
德国马牌与松赞建立合作 携手打造天人之际无忧出行上海2024年7月25日 /美通社/ -- 近日,全球领先的轮胎制造商德国马牌轮胎与本土精品度假酒店集团松赞集团宣布达成合作,以「天人之际 马上无忧」为主题,将目光聚焦滇2024-07-25
-
菲仕兰发布半年报 2024年开局强劲北京2024年7月25日 /美通社/ -- 2024年7月24日下午,荷兰皇家菲仕兰发布半年报,2024年上半年开局强劲。高附加值产品业绩表现稳健,虽然因牛奶价格下降和货币折算效2024-07-25